The object of this analysis was to develop a population pharmacokinetic model of micafungin, a new anti-fungal agent of the echinocandin class, to optimize dosing in Japanese patients with fungal infections. Population pharmacokinetics parameters were determined using NONMEM based on pharmacokinetic data from 198 subjects in seven clinical studies, comprising four phase I, two phase II and one pediatric phase III study. The healthy subjects received intravenous infusion of 2.5-150 mg micafungin. Adult and pediatric patients, age range of 8 month to 15 yeras old, were received 25-150 mg and 1-6 mg W kg daily, respectively. A total of 1825 micafungin plasma samples were available for this analysis. Two-compartment pharmacokinetic model was adopted. The clearance of micafungin was in‰uenced by body weight in children and platelet counts (PLT). However the PLT accounted for less than 20z of the variation of micafungin clearance in Japanese subjects. In conclusions, body weight is the primary covariate factor in pediatric patients. The dose adjustment by body weight would be required only pediatric patients for the micafungin therapy in Japanese patients with fungal infection.
Introduction
Micafungin is a semi-synthetic lipopeptide antifungal agents in the echinocandin class that is a inhibitor of 1,3-b-D-glucan synthase, an enzyme involved in the synthesis of the fungal cell wall. [1] [2] [3] Micafungin wasˆrst launched in Japan as Fungard TM and was recently launched in the US as Mycamine TM . 4) However, theˆrst registered anti-fungal agent to gain FDA approval and be marketed in the US was caspofungin. 5) These potent agents caused few adverse events and drung interaction, but is available only as an intravenous formulation. 6) Several papers have been published describing the pharmacokinetics of some of the echinocandins, including caspofungin, 7) micafungin [8] [9] and anidulafungin. 10) These papers report linear pharmacokinetics with long elimination half-lives for once-daily doses, which appear to be metabolized in the liver.
Micafungin has been reported to be well-tolerated in healthy subjects, 11) and has also demonstrated eŠective-ness in patients with deep-seated mycosis. 12) Seven Japanese clinical studies were recently conducted; three with healthy subjects, one with elderly subjects, two with adult patients, and one with pediatric patients with fungal infection. The pharmacokinetics of micafungin in healthy subjects revealed a low clearance of 0.197 mL W min W kg. The elimination half life was 13.9 h over the dose range of 12.5 to 150 mg, 7) and the urinary recovery was less than 1z. It has been reported by Herbert et al. that renal dysfunction dose not alter micafungin pharmacokinetics. 13) In addition, the pharmacokinetics of adult patients were consistent with those obtained for healthy adults. 14) Based on thesê ndings, the pharmacokinetics proˆle of micafungin is considered to be linear over this dose range for both adult patients and healthy subjects. In a US study, however, the clearance in febrile neutropenic pediatric patients was found to be approximately 1.35 times that 15) Recently, micafungin gained approval for pediatric use in Japan; therefore the dosing recommendations for pediatric patients need to be determined using the population pharmacokinetics approach.
In this article, the development of a micafungin population pharmacokinetics model using plasma concentration data collected from the seven Japanese clinical studies mentioned above is described. The optimal dose for both adults and pediatric patients with fungal infection is also presented.
Methods
Subjects and trial design: Seven clinical trials conducted in Japan between 1997 and 2004 are listed in Table 1 . These studies were all performed in accordance with the Declaration of Helsinki, with ethnics committee approval, and with the informed consent of each subjects. The subject characteristics are summarized in Table 1 . In the phase I trials, 27 subjects were given a single intravenous 2.5, 10, 25, or 50 mg infusion of micafungin over 2 hours (P-1), and 6 subjects were given 25 mg once daily (1 hour infusion) for 7 days (P-2). Large numbers of plasma concentration data were collected for the pharmacokinetic analysis. Trial FJ-463-0003 was an open-label phase II study that demonstrated safety and e‹cacy results in adult patients with deep-seated mycosis. A maximum of three blood samples were collected from each patients at the following time points; completion of infusion, around 2 hours after the infusion was completed, and 24 hours post-dose. These samples were subjected to pharmacokinetic analysis.
The studies FJ-463-0004 and -0005 were conducted to evaluate the diŠerence between the pharmacokinetics of elderly and non-elderly patients, and to demonstrate pharmacokinetic linearity at clinically eŠective dose levels, respectively. FJ-463-0006 was a phase III trial in patients with sever or refractory deep-mycosis. These patients were given 25, 50, 75, 100 or 150 mg of micafungin daily. FJ-463-FP01 was the only phase III trial conducted with pediatric patients. The dosage was determined according to body weight for children. Ninety pediatric patients ranging from 8 months to 15 years old, were given 1, 2, 3 or 6 mg W kg of micafungin daily. One to three blood samples were collected for pharmacokinetics analysis from each patient in the Phase II and III studies.
Plasma concentrations and background data: All plasma concentrations were determined using highperformance liquid chromatography (HPLC) with a ‰uorescence detector 16) at the same laboratory among studies. Figure 1 illustrates the plasma concentrationtime data for micafungin. A total of 1,825 sets of plasma concentration-time course data were collected from the 198 subjects (82 healthy adult subjects, 97 adult patients and 19 pediatric patients) who participated in the seven clinical trials. The clinical laboratory test data were taken from a data set created by selecting the data needed from a clinical study database containing data from the case report forms that had been summarized and veriˆed according to the methods speciˆed in the clinical study SOPs. The following potential covariate factors were treated as a background data;, age (AGE, years), weight (WGT, kg), red blood cell count (RBC, 10 4 W mL), hematocrit (HCT, z), platelet count (PLT, 10
, creatinine clearance [CCR, mL W min; calculated from the serum creatinine value (SCR, mg W dL) using the Cockcroft-Gault equation 17) [CCR＝(140 -AGE)×WT W (72×SCR)× 0.85 SEX , where SEX is categorical parameter of gender (female＝1, male＝0)], body mass index (BMI, kg W m 2 ). Handling of typical clinical laboratory data: For each subject's clinical laboratory test data, the initial plasma concentration observation time point was typically used as the actual time point. If the value for the initial observation was missing, the nearest time point before or after the initial time point (an earlier time point was used if both were the same time window from the initial time point) was taken as the same plasma concentration time point.
Analysis of population pharmacokinetics: The plasma concentration and the background data were combined to create a data set for analysis. The data set was created using SAS (version 6.12, SAS Institute, Japan).
The population analysis was performed using a nonlinear mixed eŠect model program, NONMEM.
18) The following software and hardware were used in the analysis, NONMEM (double precision, version V, level The population pharmacokinetic parameters were assumed to have log-normal distribution and the relative error model was also assumed for the residual error. Inter-subject variability was initially included for all parameters.
The minimum value of the object function (MOF) was used to discriminate between various models. A diŠerence in MOF (DMOF) of 3.84 for 1 degree of freedom (pº0.05) was considered statistically sig- niˆcant. Empirical Bayesian estimation of parameters: Empirical Bayesian estimates of the parameters for each subject were determined by means of the posthoc option of the NONMEM estimation step, using the population parameters of the basic model. Examination ofˆxed eŠect model: Possible covariate candidates were selected given the results of a simple linear regression between background data and posthoc CL.
Each covariate was independently incorporated into the basic model. The MOF was used to discriminate between the various models as described above.
Results and Discussion
The demographics and characteristics of Japanese subjects are summarized in Table 1 . FJ-464-FP01 was the only study in which in pediatric patients were investigated. A total of 198 subjects and plasma micafungin concentrations at 1825 time points were included in the analysis. Figure 1 shows the plasma concentration-time courses for both healthy subjects (A) and patients (B). The concentration data from patients were assumed to be steady-state data in the analysis. No concentration data outliers were included in the analysis. The clinical laboratory test data are summarized in Table 2 .
Basic population model building: A two-compartment pharmacokinetic model was adopted to describe micafungin pharmacokinetics. First of all, inter-individual variability were included in all parameters, clearance (CL), volume of distribution (V), inter-compartmental clearance (Q), and steady-state volume of distribution (Vss), as a full model. When the inter-individual 
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DMOF is the diŠerence of object function values against model c111, TVCL means clearance of subject with typical description data and clinical laboratory value, u presents proportionality factor (ˆxed eŠect). The covariate factors were treated as values centering from mean value. Signiˆcance (signiˆcance criterion was DMOFÃ-3.84, pº0.05) variability of CL, V and Vss was assumed to be the same, the maximum value of DMOF against full model was obtained in this model building step. However, the regression terminated prematurely and unexpectedly, before the maximum likelihood estimate could be obtained. When the inter-individual variance for Q was eliminated from the model described above, the convergence improved. For this reason, this was used as the basic population model. The population mean for the clearance was 11.9 mL W min, with an inter-individual variability of 40.6z and a residual error of 11.0z. The estimated error for these parameters was 2.9z, 21.8z, and 16.6z, respectively. Non-compartment analysis was performed to evaluate the reliability of estimation by the population pharmacokinetic analysis using either proˆling data from healthy subjects or three corresponding points from the healthy subject and patient data. The clearance value compared with the posthoc CL ( Fig. 2A and 2B) . In both plots, the data fell either on or symmetrically near the unit line, considering the posthoc CL was reliable.
Fixed eŠect model building: A simple regression analysis was performed to investigate the covariates of posthoc CL. For all subjects, WT, Age, PLT, ALB and BMI were chosen for the considerable covariates of micafungin clearance. Because of the diŠerence in body weight between adults and children, the regression analyses were also evaluated by each age group. The covariate candidates were assumed to be ALB, HCT, and RBC for adult, WT and AGE for children, respectively. Aˆxed eŠect model for clearance was evaluated by means of the forward addition method using NONMEM. WT was the most signiˆcant covariate value for all patients (c110), and AGE, PLT, BMI, and ALB in order. When the WT was tested for children (model c111), the greatest DMOF was obtained ( Table 3) . The inter-individual variability was decreased 24.1z from the value seen in basic model. That is, body weight in‰uence on clearance in pediatric patients. Additionally, another covariate was explored. Since it was considered that AGE was not associated with weight-corrected clearance as shown in Fig. 6B , AGE was skipped for the evaluation because. PLT was found to be a signiˆcant covariate, although the signiˆcance was considerably week ( Table 4) . Scatter plots of the posthoc CL values versus PLT are shown in Fig. 3 . Then we decided that model c120 was theˆnal micafungin population pharmacokinetic model. The diagnostic plots demonstrated a lack of bias and goodˆt of the model to plasma concentrations (Fig. 4 and Fig. 5 ). Thê nal parameters were presented in Table 5 , and theˆxed eŠect model for CL as follows, CL＝13.0＋0.228×(WT-52.3)×FIX＋0.0345×(PLT-21.6) [ Theˆxed eŠect contributed to the clearance in subjects possessing the maximum and minimum covariate values yielded 71.9z and 19.7z in body weight and PLT, respectively. It mean that the PLT is a meaningless parameter to explain variability on the micafungin clearance. Thus the body weight is considered to be the primary variation factor for pediatric patients.
Posthoc CL values from theˆnal model were plotted versus age (Fig. 6A) . The body weight-corrected CL show the constant values across the age (Fig. 6B) . This observation is supported by the fact that no agedependence was seen for the weight-corrected posthoc CL value (mL W min W kg).
Conclusion: Micafungin clearance was in‰uenced by body weight (in children) as well as platelet count. PLT accounted for less than 20z of the variation of micafungin clearance in Japanese subjects. Therefore, we concluded that body weight is the primary factor of variation in pediatric patients, which indicates that establishing a dose per unit body weight (mg W kg) for pediatric patients, not required for adults, would provide the same plasma micafungin concentrations seen in adults.
